This site already covers palmitoylethanolamide (PEA) and anxiety, where the mechanism runs through neuroinflammation. Mood disorders are a separate question with a separate, and in some respects stronger, evidence base: there are two actual randomized, double-blind, placebo-controlled trials of PEA as an add-on in psychiatry, one in major depressive disorder and one in acute mania.
Both were positive. Both were small, both came from the same Iranian research network, and neither has been independently replicated. That combination, real randomized evidence that is nonetheless preliminary, is worth walking through carefully, because it sits in an uncomfortable middle ground between the overstated claims on supplement pages and the dismissal PEA often gets for being a “food supplement.”
Key Takeaways
- A 2018 randomized, double-blind, placebo-controlled trial in 58 patients with major depressive disorder found PEA 600 mg twice daily added to citalopram produced significantly greater symptom reduction, with a difference detectable by week 2 [1].
- Response rate at six weeks was 100% in the PEA group versus 74% on placebo, with no difference in side effects [1]. That is a striking figure from a 54-completer trial and needs replication before it means much.
- A 2022 randomized, double-blind, placebo-controlled trial in 63 patients with acute mania found PEA 600 mg twice daily added to lithium and risperidone significantly reduced Young Mania Rating Scale scores at weeks 4 and 6 [2].
- A non-randomized 2024 study in COVID-19 survivors found PEA improved depression and fatigue but not chronic pain or general wellbeing [3].
- Every trial used PEA on top of a prescribed psychiatric medication, never instead of one. There is no evidence for PEA as a standalone treatment for any mood disorder.
The Inflammation Hypothesis of Depression, and Where PEA Fits
The rationale for testing an anti-inflammatory lipid in depression comes from two directions that meet in the middle.
The first is the endocannabinoid system, which regulates mood and stress response and which PEA interacts with. As a 2019 review in Journal of Affective Disorders lays out, PEA targets PPAR-alpha, binds the G-protein-coupled receptor GPR55, and has weak affinity for CB1 and CB2 receptors. Preclinical work has shown antidepressant-like activity in animal models of depression, including depression associated with neuropathic pain and traumatic brain injury [4].
The second is the observation that PEA levels themselves shift with psychiatric state. A 2024 study in BMC Medicine measured serum endocannabinoids and related fatty acyl compounds alongside tryptophan and kynurenine in 51 patients with depressive disorder and 31 healthy volunteers. It found that in people without depressive symptoms, PEA correlated directly with tryptophan, while in people with depressive symptoms that relationship was lost and replaced by correlations among the endocannabinoid compounds themselves. The authors interpreted this as altered endocannabinoid metabolism in depression [5].
That is an association study, not a treatment study, and it cannot say whether disrupted PEA signaling causes depressive symptoms or results from them. What it does establish is that PEA is not an arbitrary compound to be testing here.
The Major Depression Trial
The 2018 trial, published in Journal of Affective Disorders, randomized 58 patients with DSM-5 major depressive disorder and a Hamilton Depression Rating Scale score of 19 or higher to receive either PEA 600 mg twice daily or matched placebo, in addition to citalopram, for six weeks. Fifty-four completed. HAM-D was assessed at baseline and weeks 2, 4, and 6 [1].
By week 2, the PEA group had a significantly greater HAM-D reduction than placebo (8.30 versus 5.81 points, P = .004). Across the full trial period the PEA group showed significantly greater improvement overall. At six weeks, the response rate, defined as at least a 50% reduction in HAM-D, was 100% in the PEA group versus 74% on placebo (P = .01). Baseline characteristics and side effect frequency did not differ between groups [1].
The speed is the part clinicians would care about most. Standard antidepressants typically take four to six weeks to produce clear separation from placebo, and that lag is one of the biggest practical problems in treating depression. A difference appearing at week 2 is exactly the kind of finding worth pursuing.
The reasons to hold that finding loosely are equally clear. The authors themselves list a small population and short follow-up as limitations, and note the effect was seen in a predominantly male sample. A 100% response rate in any psychiatric trial arm is an outlier result that would be unusual to reproduce. And a single-center trial from one research group is exactly the situation where independent replication matters most.
The Acute Mania Trial
The second randomized trial, published in Psychiatry and Clinical Neurosciences in 2022, tested a harder scenario. Patients in the acute phase of mania were assigned to either lithium (blood level 0.8 to 1.1 mEq/L) plus risperidone 3 mg plus PEA 600 mg twice daily, or the same regimen with placebo, for six weeks. Sixty-three patients completed, 32 on PEA and 31 on placebo, and were assessed with the Young Mania Rating Scale, the Hamilton Depression Rating Scale, and the Extrapyramidal Symptom Rating Scale [2].
There was a significant time-by-treatment interaction on YMRS scores across the trial (P = .004), with the PEA group showing significantly greater decreases at weeks 4 and 6 (P = .018 and P = .002). Extrapyramidal symptom scores did not differ between groups, meaning PEA neither caused nor prevented the movement side effects associated with risperidone [2].
The authors called this preliminary evidence and stated directly that larger samples and longer follow-up are needed. Acute mania is a psychiatric emergency treated in hospital with mood stabilizers and antipsychotics. Nothing about this trial suggests PEA belongs anywhere in that picture except as an adjunct being studied under supervision.
A related systematic review examined PEA across psychosis more broadly and found 13 eligible studies, 11 in humans. Observational work consistently showed increased PEA levels in psychosis patients, which the authors interpreted as a possible early compensatory response that appears to be lost over the longer term. Three human studies found oral PEA supplementation reduced negative psychotic and manic symptoms with no serious adverse events [6].
The Post-COVID Study, and Why Its Design Matters
A 2024 study in International Clinical Psychopharmacology evaluated 98 patients presenting with neuropsychiatric symptoms at a post-COVID outpatient clinic. All were offered micronized/ultramicronized PEA 600 mg twice daily for three months. The 57 who accepted were compared with the 41 who declined [3].
The groups did not differ at baseline on demographics, comorbidities, psychiatric history, antidepressant therapy, acute COVID severity, or baseline neuropsychiatric status. Those who took PEA showed significantly greater improvement in depression and fatigue. Notably, there was no association with change in chronic pain or subjective wellbeing, which is a selective pattern rather than a generalized “everything improved” result. On multivariable analysis, PEA predicted neuropsychiatric improvement independently of age, sex, and baseline status [3].
The design limitation is fundamental and the authors acknowledge it: this was retrospective and patients self-selected into treatment. People who accept a three-month supplement regimen differ systematically from people who decline, in ways that baseline matching on measured variables cannot fully address. The selective outcome pattern is somewhat reassuring against pure placebo response, but this study cannot establish efficacy.
How to Read This Overall
PEA in mood disorders has better evidence than most supplements marketed for mood: two genuine randomized, double-blind, placebo-controlled trials with positive primary outcomes and no signal of harm. It also has worse evidence than the trial designs suggest at first glance, because both trials are small, both come from the same research network, and neither has been replicated independently.
The dose was consistent at 600 mg twice daily, at the upper end of the range discussed in this site’s dosage guide, and every trial ran it alongside a prescribed psychiatric medication. Adverse events were not elevated relative to placebo in either randomized trial, which is consistent with the broader safety picture covered in the side effects article.
Anyone with depression or bipolar disorder should treat this as a topic for their psychiatrist rather than a self-directed experiment, for a specific reason beyond the usual caution: the antidepressant trial studied PEA added to citalopram, and the mania trial studied it added to lithium and risperidone. Substituting a supplement for either of those medications is not what was tested, and in bipolar disorder in particular, stopping a mood stabilizer carries serious risk. Adding anything to a psychiatric regimen also needs a prescriber’s review for interactions, which this site covers separately.
Frequently Asked Questions
Has PEA been tested as a standalone antidepressant?
No. Both randomized trials used PEA as an add-on to prescribed medication [1][2]. There is no published evidence on PEA alone for depression.
How fast did the antidepressant effect appear?
The PEA group showed significantly greater HAM-D reduction than placebo by week 2 [1], which is faster than the typical four-to-six-week separation seen with standard antidepressants. It is a single trial finding.
What dose was used?
600 mg twice daily, so 1200 mg per day, in both randomized trials. The post-COVID study used the same 600 mg twice daily of micronized/ultramicronized PEA.
Does PEA interact with antidepressants or lithium?
No interaction signal appeared in these trials, where PEA was combined with citalopram in one and with lithium plus risperidone in the other, and side effect rates did not differ from placebo. That is not the same as a formal interaction study. This site covers PEA drug interactions in a dedicated article, and any addition to a psychiatric regimen should go through the prescriber.
Why is the evidence considered preliminary if the trials were randomized?
Sample sizes were 54 and 63 completers, follow-up was six weeks in both, and both came from the same research network without independent replication. Randomization removes some biases; it does not make a small unreplicated trial definitive.
References
- Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, et al. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J Affect Disord (2018). PMID 29486338
- Abedini T, Hosseyni R, Ghannadi F, et al. Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial. Psychiatry Clin Neurosci (2022). PMID 35737597
- Merolla A, De Lorenzo R, Paolazzi G, et al. Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors. Int Clin Psychopharmacol (2024). PMID 38381905
- De Gregorio D, Manchia M, Carpiniello B, et al. Role of palmitoylethanolamide (PEA) in depression: Translational evidence. J Affect Disord (2019). PMID 30391203
- Comai S, Nunez N, Atkin T, et al. Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptoms. BMC Med (2024). PMID 38273283
- Bortoletto R, Piscitelli F, Candolo A, et al. Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence. Front Psychiatry (2023). PMID 37533892
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
